Drug information of Sacubitril and valsartan

Sacubitril and valsartan

Drug group:

Sacubitril and valsartan is a combination medicine used in certain people with chronic heart failure. sacubitril and valsartan helps lower the risk of needing to be hospitalized when symptoms get worse, and helps lower the risk of death from heart failure.

Mechanism of effect

Sacubitril: Neprilysin inhibitor; neprilysin is responsible for degradation of atrial and brain natriuretic peptide; the cardiovascular and renal effects of sacubitril’s active metabolite (LBQ657) in heart failure are attributed to the increased levels of peptides that are degraded by neprilysin (eg, natriuretic peptide); administration results in increased natriuresis, increased urine cGMP, and decreased plasma MR-proANP and NT-proBNP

Valsartan: Angiotensin II receptor type I inhibitor; decreases blood pressure and blocks vasoconstrictor and aldosterone-secreting effects of angiotensin II


significantly increased urine ANP and cGMP and plasma cGMP, and decreased plasma NT-proBNP, aldosterone and endothelin-1. In clinical studies, this combination had no effect on QTc interval.


Absolute bioavailability

  • Sacubitril: ≥60%
  • Valsartan in Entresto is more bioavailable than the valsartan in other marketed tablet formulations; 26 mg, 51 mg, and 103 mg of valsartan in Entresto is equivalent to 40 mg, 80 mg, and 160 mg of valsartan in other marketed tablet formulations, respectively


  • Reached in 3 days
  • At steady state, sacubitril and valsartan do not accumulate significantly, whereas LBQ657 accumulates by 1.6-fold

Peak plasma concentration

  • Sacubitril: 0.5 hr
  • LBQ657: 2 hr
  • Valsartan: 1.5 hr

Protein bound

  • Sacubitril: 94-97%
  • LBQ657: 94-97%; LBQ657 crosses the blood-brain barrier to a limited extent (0.28%)
  • Valsartan: 94-97%


  • Sacubitril: 103 L
  • Valsartan: 75 L


Sacubitril is a prodrug that is metabolized by esterases to the active metabolite LBQ657

LBQ657 is not further metabolized to a significant extent

Valsartan is minimally metabolized; only about 20% of the dose is recovered as metabolites; a hydroxyl metabolite has been identified in plasma at low concentrations (<10%)


  • Sacubitril: 1.4 hr
  • LBQ657: 11.5 hr
  • Valsartan: 9.9 hr


  • Sacubitril: 52-68% (primarily as LBQ657) in urine; 37-48% (primarily as LBQ657) in feces
  • Valsartan: 13% in urine; 86% in feces



Heart Failure

Recommended starting dose: 49 mg/51 mg PO BID

Target maintenance dose: After 2-4 weeks, double the dose to the target maintenance dose of 97 mg/103 mg PO BID as tolerated


Safety and efficacy not established

Side effects

vertigo , Cough , Hyperkalemia


  • Not for use in patients with hereditary angioedema; observe for signs and symptoms of angioedema; if angioedema occurs, discontinue drug immediately, provide appropriate therapy, and monitor for airway compromise
  • Sacubitril/valsartan lowers blood pressure and may cause symptomatic hypotension; patients who are volume-depleted or salt-depleted, or those taking diuretics, are at greater risk
  • Monitor renal function and potassium levels in susceptible patients (eg, diabetes, hypoaldosteronism, high-potassium diet, renal artery stenosis); dosage reduction or interruption may be required

·         Black Box Warnings

  • Discontinue as soon as possible when pregnancy is detected
  • Drug affects renin-angiotensin system, causing oligohydramnios, which may result in fetal injury or death

Points of recommendation

  • Follow all directions on your prescription label. Your doctor may occasionally change your dose to make sure you get the best results. Do not take this medicine in larger or smaller amounts or for longer than recommended.
  • You may take sacubitril and valsartan with or without food. Take the medicine at the same time each day.
  • Your blood pressure will need to be checked often. Your kidney function may also need to be checked.
  • Store this medicine in the original container at room temperature away from moisture and heat.
  • Take the missed dose as soon as you remember. Skip the missed dose if it is almost time for your next scheduled dose. Do not take extra medicine to make up the missed dose.

Pregnancy level

Not assigned

Ask a Pharmacist

User's questions
    No comments yet.